KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Liabilities and Shareholders Equity (2020 - 2025)

Ginkgo Bioworks Holdings (DNA) has disclosed Liabilities and Shareholders Equity for 4 consecutive years, with $2.0 billion as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Liabilities and Shareholders Equity rose 8.32% year-over-year to $2.0 billion, compared with a TTM value of $6.7 billion through Dec 2023, up 4.14%, and an annual FY2022 reading of $2.5 billion, up 22.61% over the prior year.
  • Liabilities and Shareholders Equity was $2.0 billion for Q3 2023 at Ginkgo Bioworks Holdings, down from $2.3 billion in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $2.5 billion in Q4 2022 and bottomed at $675.2 million in Q4 2020.
  • Average Liabilities and Shareholders Equity over 4 years is $2.0 billion, with a median of $2.1 billion recorded in 2022.
  • The sharpest move saw Liabilities and Shareholders Equity surged 206.74% in 2021, then fell 13.01% in 2022.
  • Year by year, Liabilities and Shareholders Equity stood at $675.2 million in 2020, then soared by 206.74% to $2.1 billion in 2021, then increased by 22.61% to $2.5 billion in 2022, then decreased by 20.2% to $2.0 billion in 2023.
  • Business Quant data shows Liabilities and Shareholders Equity for DNA at $2.0 billion in Q3 2023, $2.3 billion in Q2 2023, and $2.4 billion in Q1 2023.